PRN: Global Veterinary Clostridium Vaccine Market to Grow at a CAGR of 4.9% by 2021: Manufacturing & Storage Issues Remain a Challenge

27/lug/2017 14:01:03 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Veterinary Clostridium Vaccine Market to Grow at a CAGR of 4.9% by 2021: Manufacturing & Storage Issues Remain a Challenge


DUBLIN, July 27, 2017 /PRNewswire/ --

The "Global Veterinary Clostridium Vaccine Market 2017-2021" report has been added to Research and Markets' offering.

Research and Markets Logo

The global veterinary clostridium vaccine market to grow at a CAGR of 4.96% during the period 2017-2021.

The report, Global Veterinary Clostridium Vaccine Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is inorganic growth strategies. The veterinary clostridium vaccine market has been witnessing an increasing trend in strategic alliances and acquisitions among vendors. The vendors are planning for inorganic growth strategies such as acquisitions and partnerships to boost the research and to improve its penetration in emerging markets.

According to the report, one driver in the market is advances in technology. The advances in technology have improved the overall pharmacokinetics and dynamics of vaccines along with cost-effective processes. The use of cell line culture in manufacturing viral vaccinations has been increased, which improved the quality of vaccinations. For instance, Valneva SE developed EB66 cell line, which can be used for high-efficiency vaccine production. This cell line is derived from stem cells of duck embryo. This can be used for large-scale manufacturing of veterinary vaccines.

Further, the report states t! hat one challenge in the market is manufacturing and storage issues. A vaccine involves a complex network of processes ranging from manufacturing to delivery. The cost-intensive manufacturing issues associated with vaccines get quadrupled with strict regulatory laws. The protocol set by the FAO for manufacturing animal vaccines has rigorous processes like master seed and master stock analysis. These processes are crucial to producing quality vaccines, as they involve analysis of microbes, which are used in vaccine manufacturing followed by sterilization process and storage process.

Key vendors

  • Elanco
  • Merck
  • Merial
  • Zoetis

Other prominent vendors

  • Advaxis
  • Aratana Therapeutics
  • ARKO Labs
  • Bayer
  • CanFel Therapeutics
  • Ceva
  • Colorado Serum Company
  • Epitopix
  • Genus
  • Hygieia Biological Laboratories
  • Nuovo Biologics
  • Valneva SE
  • Vetoquinol
  • Virbac

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: An overview of Clostridial Disease

PART 06: Market landscape

PART 07: Market segmentation by species type

PART 08: Geographical segmentation

PART 09: Decision framework

PART 10: Drivers and challenges

PART 11: Market trends

PART 12: Vendor landscape

PART 13: Key vendor analysis

PART 14: Appendix

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

blog comments powered by Disqus è un servizio offerto da Factotum Srl